Systems and methods for providing personalized radiation therapy

Patent metadata

Field	Value
Publication number	US-10697023-B2
Application number	US-201615571617-A
Country	US
Kind code	B2
Filing date	May 5, 2016
Priority date	May 5, 2015
Publication date	Jun 30, 2020
Grant date	Jun 30, 2020

Abstract

An example method of treating a subject having a tumor is described herein. The method can include determining a radiosensitivity index of the tumor, deriving a subject-specific variable based on the radiosensitivity index, and obtaining a genomic adjusted radiation dose effect value for the tumor. The radiosensitivity index can be assigned from expression levels of signature genes of a cell of the tumor. Additionally, the genomic adjusted radiation dose effect value can be predictive of tumor recurrence in the subject after treatment. The method can also include determining a radiation dose based on the subject-specific variable and the genomic adjusted radiation dose effect value.

First claim

What is claimed is:

1. A method of treating a subject having a tumor, comprising:
determining a radiosensitivity index of the tumor, the radiosensitivity index being assigned from expression levels of one or more signature genes;
deriving a subject-specific variable based on the radiosensitivity index;
obtaining a genomic adjusted radiation dose effect value for the tumor, the genomic adjusted radiation dose effect value being predictive of tumor recurrence in the subject after treatment;
determining a radiation dose based on the subject-specific variable and the genomic adjusted radiation dose effect value; and
administering radiation therapy to the subject based upon the determined radiation dose.

2. The method of claim 1 , wherein determining a radiation dose further comprises determining a radiation dose per treatment or a number of radiation treatments.

3. The method of claim 1 , wherein the genomic adjusted radiation dose effect value for the tumor comprises a range of values predictive of tumor recurrence in the subject after treatment.

4. The method of claim 1 , wherein the genomic adjusted radiation dose effect value for the tumor is indicative of a low chance of tumor recurrence in the subject after treatment.

5. The method of claim 1 , wherein the genomic adjusted radiation dose effect value for the tumor is specific to a type of cancer.

6. The method of claim 5 , wherein the type of cancer comprises breast, lung, prostate, glioblastoma, head and neck, pancreas, esophagus, or colorectal cancer.

7. The method of claim 1 , further comprising determining the genomic adjusted radiation dose effect value using a univariate or multivariate analysis of genomic dose effect value and outcome for a group of subjects.

8. The method of claim 1 , wherein the subject-specific variable provides a measure of the tumor's ability to accumulate radiation damage.

9. The method of claim 1 , wherein the subject-specific variable is derived using a linear quadratic model for cell survival, the radiosensitivity index being approximately equal to cell survival.

10. The method of claim 1 , wherein the one or more signature genes comprise at least one of Androgen receptor (AR); Jun oncogene (c-Jun); Signal transducer and activator of transcription 1 (STAT1); Protein kinase C, beta (PRKCB or PKC); V-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA or p65); c-Abl oncogene 1, receptor tyrosine kinase (ABL1 or c-Abl); SMT3 suppressor of mif two 3 homolog 1 ( S. cerevisiae ) (SUMO1); p21 (CDKN1A)-activated kinase 2 (PAK2); Histone deacetylase 1 (HDAC1); or Interferon regulatory factor 1 (IRF1).

Assignees

• H Lee Moffitt Cancer Ct & Res

Inventors

• Scott Jacob
• Torres-Roca Javier F

Classifications

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/158

  Expression markers · CPC title

• G16B40/00

  ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding · CPC title

• G16B25/10

  Gene or protein expression profiling; Expression-ratio estimation or normalisation · CPC title

• G16H20/40

  relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture · CPC title